Skip to main content
logo
Agios Pharmaceuticals, Inc. (LON:0HB0)
London flag London · Delayed Price · Currency is GBP · Price in USD
27.65
+1.35 (5.13%)
Feb 12, 2026, 2:56 PM GMT

Agios Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
54.0336.526.8214.24-
Revenue Growth (YoY)
48.03%36.07%88.36%--
Cost of Revenue
6.35305.45298.41281.61256.97
Gross Profit
47.68-268.95-271.58-267.37-256.97
Selling, General & Admin
180.28156.78119.9121.67121.45
Research & Development
339.54----
Operating Expenses
519.82156.78119.9121.67121.45
Operating Income
-472.13-425.74-391.49-389.05-378.42
Interest & Investment Income
56.3848.0833.3412.790.84
Other Non Operating Income (Expenses)
1.966.496.0616.621.07
EBT Excluding Unusual Items
-413.8-371.17-352.09-359.65-356.51
Gain (Loss) on Sale of Assets
-200---
Other Unusual Items
-889.14-127.85-
Pretax Income
-413.8717.97-352.09-231.8-356.51
Income Tax Expense
-1.0244.24---
Earnings From Continuing Operations
-412.78673.73-352.09-231.8-356.51
Earnings From Discontinued Operations
----1,961
Net Income
-412.78673.73-352.09-231.81,605
Net Income to Common
-412.78673.73-352.09-231.81,605
Shares Outstanding (Basic)
5857565560
Shares Outstanding (Diluted)
5858565560
Shares Change (YoY)
0.14%4.02%1.57%-9.36%-12.39%
EPS (Basic)
-7.1211.86-6.33-4.2326.55
EPS (Diluted)
-7.1211.64-6.33-4.2326.55
Free Cash Flow
--391.53-297.06-314.36-413.06
Free Cash Flow Per Share
--6.76-5.34-5.74-6.83
Gross Margin
88.26%----
Operating Margin
-873.87%-1166.47%-1459.52%-2732.07%-
Profit Margin
-764.01%1845.92%-1312.63%-1627.82%-
Free Cash Flow Margin
--1072.73%-1107.49%-2207.58%-
EBITDA
-466.92-420.08-384.86-380.48-369.18
D&A For EBITDA
5.215.656.628.569.24
EBIT
-472.13-425.74-391.49-389.05-378.42
Effective Tax Rate
-6.16%---
Revenue as Reported
54.0336.526.8214.24-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.